The Global Market for Stem Cell Technologies is Forecast to Reach US$29.3 Billion by 2024
Rising Demand for Regenerative Medicine Aided by the
Growing Burden of Chronic Diseases to Drive the Global Stem Cells Market, According
to a New Report by Global Industry Analysts, Inc.
GIA launches
comprehensive analysis of industry segments, trends, growth drivers, market
share, market size and demand forecasts on the global Stem Cells market. The global market for Stem Cell technologies is forecast
to reach US$29.3 billion by 2024, driven by factors such as continuous discovery of
new sources of stem cells, innovative new methods for their acquisition and
harvesting, increasing incidence of chronic diseases and rising demand for
regenerative medicine.
Growing demand
for stem cells in regenerative therapy, aided by increasing incidence of
chronic diseases, is expected to drive the stem cells market. Most of the
revenue from regenerative medicine is attributable to demand for stem cell
therapy in the treatment of neurological disorders, such as Parkinson’s
disease, Huntington’s chorea, and suchlike. Robust investments in healthcare
R&D also boosts the market. Other key drivers in the market include rising
government support for the medical sector, growing personal disposable incomes
presence of health insurance, and increasing medical tourism to low cost
countries. U.S., Korea, and China represent heavy investors in clinical
investigations using stem cell products, accounting for a major share of stem
cell clinical trials conducted worldwide.
While embryonic stem cells have been used for their superior efficacy
and wide appeal, adult stem cells are increasingly gaining favour among researchers
because they are sourced ethically and are less susceptible to immune
rejection. There are currently several research studies seeking to validate the
efficiency of adult tissue-derived stem cells when used in lieu of embryonic
stem cells. Induced Pluripotent Stem Cells (iPSCs) represent another area
revolutionizing the stem cell research space. The recent years witnessed major
developments in the iPSC space, in terms of biobanking, differentiation
technologies and applications in clinical research and potential therapeutics.
iPSC thus represents a major trend that offers promise for the treatment of
many incurable diseases.
Several human trials with Mesenchymal Stem Cells
(MSCs), which are cells extracted from fat, bone marrow and other tissues, are
also in progress. These cells are capable of modulating inflammatory response
and the immune system, and feature potential capability to treat a number of
conditions including autoimmune disorders, arthritis, and graft vs host disease
in bone marrow transplant patients. Neural stem cells extracted from either
adult or foetal brain tissue are also under testing for rare inherited brain
disorders and also for certain common conditions such as spinal cord injury in
humans.
As stated by the new market research report on Stem
Cells, the United States dominates the market for stem
cell technologies supported by huge government funding and the ensuing increase
in the number of stem cell clinical trials underway for a wide range of
diseases. Asia-Pacific ranks as the fastest growing market led by factors such
as growing interest of Southeast Asian countries in understanding and
commercializing stem cells for a range of crippling and degenerative diseases;
policy led development of networking infrastructure for stem cell research,
stem cell banking and stem cell tourism; adoption of free enterprise model by
Asian countries to encourage public and private funding and participation; and
growing focus on life sciences research to manage the growing healthcare burden
in the region.
Key players
in the market include Athersys Inc., Apceth GmbH & Co. KG, AVIVA BioSciences
Corporation, BioE Inc., Bone Therapeutics SA, Cesca Therapeutics Inc.,
Cryo-Cell International Inc., Cytori Therapeutics Inc., ESI BIO, Gamida Cell
Ltd., Holostem Terapie Avanzate, International Stem Cell Corp., Kangstem
Biotech. Ltd., Lonza Group Ltd., Mesoblast Ltd., Neuralstem Inc., Nuvasive
Inc., Osiris Therapeutics Inc., OncoMed Pharmaceuticals Inc., PROMETHERA
Biosciences S.A.N.V, Reliance Life
Sciences, ReNeuron Group Plc., STEMCELL Technologies Inc., Stemedica Cell
Technologies Inc., Stempeutics Research Pvt. Ltd., Takara Bio USA Inc., TiGenix
NV, U.S Stem Cell Inc., and ViaCord, among others.
The research
report titled “Stem Cells: A Global Strategic Business Report” announced by Global Industry Analysts
Inc., provides a comprehensive review of market trends, drivers, issues,
challenges, and other strategic activities of major companies. The report
provides market estimates and projections in dollars for all major geographic
markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK,
Spain, and Rest of Europe), Asia-Pacific (China, and Rest of Asia-Pacific),
Latin America (Brazil and Rest of Latin America), and Rest of World.
Global Industry
Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
Comments
Post a Comment